VTRS
- Viatris Inc.
()
Overview
Company Summary
Viatris Inc. is a global pharmaceutical company that focuses on providing access to high-quality, affordable medicines to patients worldwide. The company was formed through a merger between Mylan N.V. and Upjohn Inc., a subsidiary of Pfizer Inc., in November 2020.
As a leading player in the pharmaceutical industry, Viatris manufactures and supplies a wide range of generic and branded pharmaceutical products across various therapeutic areas. The company's product portfolio includes prescription drugs, over-the-counter medications, biosimilars, complex generics, and active pharmaceutical ingredients. Viatris offers treatments for diseases and conditions such as cardiovascular diseases, diabetes, respiratory disorders, gastrointestinal disorders, infectious diseases, central nervous system disorders, and many others.
Viatris operates globally, serving patients in more than 165 countries. The company strives to improve access to medicines by addressing affordability challenges and expanding healthcare options. By concentrating on both generic and specialty pharmaceuticals, Viatris aims to enhance patient outcomes and reduce healthcare costs.
Moreover, Viatris is committed to research and development, investing in the development of new and innovative treatments to meet the evolving needs of patients. The company also focuses on ensuring the safety and quality of its products through rigorous compliance with regulatory standards.
In summary, Viatris Inc. is a pharmaceutical company that specializes in providing affordable and quality medicines across a wide range of therapeutic areas. Their mission is to make a positive impact on global healthcare by expanding access to effective treatments.